Lyell Immunopharma, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $36,000 | $61,000 | $130,000 | $84.7M | $10.7M |
| Research and development | $158.7M | $171.6M | $182.9M | $159.2M | $138.7M |
| Operating expenses | $269.4M | $358.8M | $247.1M | $271.7M | $225.4M |
| Operating income | -$269.4M | -$358.8M | -$247.0M | -$187.1M | -$214.8M |
| Income tax expense | $0 | — | — | — | — |
| Net income | -$274.4M | -$343.0M | -$234.6M | -$183.1M | -$250.2M |
| Balance Sheet | |||||
| Cash and equivalents | $60.2M | $105.6M | $145.6M | $123.6M | $293.8M |
| Current assets | $260.9M | $379.6M | $554.7M | $651.3M | $626.3M |
| Total assets | $340.1M | $490.9M | $750.0M | $937.6M | $1.1B |
| Current liabilities | $49.4M | $53.8M | $34.5M | $37.0M | $46.7M |
| Total liabilities | $91.8M | $108.0M | $95.1M | $104.3M | $197.6M |
| Stockholders' equity | $248.2M | $382.8M | $655.0M | $833.3M | $929.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$150.0M | -$162.4M | -$163.7M | -$169.6M | -$126.2M |
| Depreciation and amortization | $11.5M | $19.6M | $20.2M | $18.0M | $13.6M |
| Stock-based compensation | $41.8M | $33.1M | $47.1M | $81.9M | $62.2M |
| Capital expenditure | $780,000 | $464,000 | $2.7M | $24.3M | $65.5M |
| Free cash flow | -$150.8M | -$162.9M | -$166.4M | -$193.8M | -$191.8M |
| Share repurchases | — | — | — | $0 | $0 |
| Impairments | $1.4M | $51.3M | $0 | $0 | $0 |
Shares outstanding 23.3M · Free float 48.1%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.